SG/CALL/MODERNA/100/0.1/20.09.24 | Market Closed - Euronext Paris 17:30:01 20/06/2024 BST | ||
| 3.515 EUR | +3.69% |
|
| Current month | -16.97% | ||
| 1 month | -12.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 3.595 | +6.05% |
| 19/06/24 | 3.39 | -6.48% |
| 18/06/24 | 3.625 | -9.60% |
| 17/06/24 | 4.01 | -1.23% |
| 14/06/24 | 4.06 | -11.74% |
Real-time Euronext Paris
Last update June 20, 2024 at 05:30 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| D662S | |
| ISIN | DE000SU2M6R9 |
| Date issued | 22/11/2023 |
| Strike | 100 $ |
| Maturity | 20/09/2024 (92 Days) |
| Parity | 10 : 1 |
| Emission price | 1.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.71 € |
|---|---|
| Lowest since issue | 0.785 € |
| Spread | 0.03 € |
| Spread % | 0.85% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
134.4
USD
Average target price
145.2
USD
Spread / Average Target
+8.05%
- Stock Market
- Warrants
- D662S Warrant
